Alpelisib-Where to buy Piqray in China

The approval of Alpelisib-Piqray marks the first time that the PIK3CA biomarker can be used to tailor treatment plans to a patient's genomic profile. Patients identified as having locally advanced or metastatic HR-positive and HER2-negative breast cancer should be evaluated for PIK3CA mutations by tumor or liquid biopsy. If a patient does have PIK3CA mutant disease, apelvis should be considered as part of the treatment plan once the patient has progressed on initial endocrine therapy with or without a CDK4/6 inhibitor.

According toNCCN Breast Cancer Guidelines, Apelvis is the preferred treatment option for PIK3CA-mutated breast cancer. For recurrent or stage IV breast cancer in patients with HR-positive, HER2-negative, and postmenopausal patients with PIK3CA-mutated tumors, apelviscombination with fulvestrant is an NCCN Category 1 recommendation. The FDA approved the combination of apelviswith fulvestrant for postmenopausal women and men withHR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. Eligible patients should have progressed on or following an endocrine-based regimen. PIK3CA mutations must be detected by an FDA-approved test.

The original drug of Apelis is not on the market in China, so it cannot be included in the medical insurance. Patients in need cannot yet purchase this drug from China. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). At present, there are no generic drugs of Apellis on the market. Please consult your medical consultant for specific prices and drug information of Apelis.